Susan H. Alexander's departure as Chief Legal Officer of Biogen Inc. was reported; the filing names no successor. As of November 15, 2026, Biogen Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from February 11, 2026 to March 11, 2026, naming 1 departure (Form 8-K, March 11, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Biogen Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Biogen Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-02-11 to 2026-03-11. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Biogen Inc. files it.
Also on the record for Biogen Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 10, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.1% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 12.4% of the class | 5%+ stakes | Source |
| June 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 11.3% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 8.7% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 7.48% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G, by FMR LLC | 6.4% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G/A, by PRIMECAP MANAGEMENT CO/CA/ | 10.2% of the class | 5%+ stakes | Source |
| November 10, 2025 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Biogen Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Biogen Inc. and the records around it.
Biogen Inc. elsewhere on the record
Companies that share a holder
- PRIMECAP MANAGEMENT CO/CA/ also filed stake reports on 24 other companies: Xencor Inc (Nov 2026), GRAIL, Inc. (Nov 2026), MARKETAXESS HOLDINGS INC (Nov 2026)
- STATE STREET CORPORATION also filed stake reports on 378 other companies: 4D MOLECULAR THERAPEUTICS INC (Nov 2026), ACADIA PHARMACEUTICALS INC (Nov 2026), ALBEMARLE CORP (Nov 2026)
- FMR LLC also filed stake reports on 762 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Biogen Inc.
Get an email when Biogen Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Biogen Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Biogen Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Biogen Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-11 | Out | Chief Legal Officer | 8-K, 2026-03-11 | ||
| 2026-02-11 | Reported | not named in the filing | 8-K, 2026-02-11 |
Why did they leave? What the filings say
Biogen Inc.'s filings state no reason for the departures below. Where a filing gives none, it says so here; nothing is inferred.
- Susan H. Alexander, Chief Legal Officer (filed 2026-03-11): the filing states no reason.
Who leads Biogen Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Legal Officer: Susan H. Alexander, departure reported (filed 2026-03-11). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Biogen Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Legal Officer at Biogen Inc., with the record behind each one.
Find candidates like Chief Legal Officer at Biogen Inc.Every change, in the filing's words
Departing: Susan H. Alexander, Chief Legal Officer
On March 11, 2026, Biogen Inc. (the "Company") announced that Susan H. Alexander, Chief Legal Officer, will depart from the Company effective as of the end May, 2026.
- The Company has initiated a search to identify the Company's next Chief Legal Officer.
Reported
On February 11, 2026, Caroline Dorsa, Chair of the Biogen Inc. ("Biogen" or the "Company") Board of Directors (the "Board") announced that she would not stand for re-election to the Board at the 2026 Annual Meeting of Stockholders (the "Annual Meeting").
- Ms. Dorsa's decision to not stand for reelection was not related to any disagreement with the Board or the Company on any matter relating to its operations, policies or practices.
Tools for this story
Each opens in a new tab, filled in for Biogen Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
